Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin

Jv, Sørensen; Mr, Lassen; Borris, L.; Hb, Rahr; Hp, Jensen; Hoppensteadt, Debra; Ja, Walenga; Fareed, Jawed

doi:10.1097/00001721-199202000-00009

Cited by 17 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FbDP levels subsequently increased from day 3 to 7. This trend has also been observed after total hip replacement [8,9], In the initial phase after trauma, levels of fibrinogen were inversely correlated to the ISS, but later a positive correlation developed suggesting that the extent of the posttraumatic increase in fibrinogen levels is proportional to the initial consumption. FpA and to some extent FM and FbDP were positively corre lated to ISS.…”

Section: Discussionsupporting

confidence: 64%

Fibrinogen and Fibrin Derivatives in Traumatized Patients: Relation to Injury Severity and Posttraumatic Pulmonary Dysfunction

Sørensen

Jensen

Rahr

et al. 1993

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

In a prospective study including 30 traumatized patients, levels of fibrinogen, fibrinopeptide A (FpA), fibrin monomers (FM) and fibrin degradation products (FbDP) were measured on admission and on days 1 2, 3 and 7 after the incident. High levels of FpA, FM and FbDP were observed immediately after the trauma. Fibrinogen levels increased during the first 7 posttraumatic days whereas FpA and FM decreased. FbDP was significantly higher on day 7 than on day 3. All variables were to some extent correlated to the injury severity score. FbDP were significantly lower on the day after admission in 4 patients who developed pulmonary dysfunction compared with patients without this complication.

show abstract

Section: Discussionsupporting

confidence: 64%

Fibrinogen and Fibrin Derivatives in Traumatized Patients: Relation to Injury Severity and Posttraumatic Pulmonary Dysfunction

Sørensen

Jensen

Rahr

et al. 1993

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…These results confirm the presence of abnormal coagulation activation in the nephrotic syndrome [ 10], Fraxiparin treatment did not induce a significant de crease in F 1+2 or D-dinier levels, showing that the liypercoagulable state persisted despite treatment. By contrast, in patients undergoing total hip replacement, the LMWH Logiparin (50 IU/kg/day), attenuated postoperative thrombin generation [11], However, baseline levels of coagulation activation markers were higher in our ne phrotic patients, and much higher dosages of LMWH might thus be necessary. It remains to be shown whether a reduction in the hypercoagulable state by LMWH corre lates with a reduction in thrombotic events in these patients.…”

Section: Discussioncontrasting

confidence: 67%

Pharmacokinetic Study of the Low-Molecular-Weight Heparin Fraxiparin in Patients with Nephrotic Syndrome

Alhenc‐Gelas¹,

Rossert

Jacquot

et al. 1995

Nephron

View full text Add to dashboard Cite

We studied the pharmacokinetics of the low-molecular-weight heparin (LMWH) Fraxiparin in 6 patients with the nephrotic syndrome. Maximal plasma anti-Xa activity was obtained 5 h after a subcutaneous injection of 60 IU anti-Xa/kg. Anti-Xa activity was no longer detectable 24 h postinjection. These results are similar to those obtained with the same dosage in other clinical settings. The biological response to a daily subcutaneous injection of 60 IU anti-Xa/kg was studied for 8 days. No cumulative effect was observed. All the patients had an abnormal activation state of hemostasis mechanisms before treatment, as shown by high prothrombin fragment 1 +2 and D-dimer levels, which were not decreased by Fraxiparin. It remains to be determined whether a higher dosage of LMWH might attenuate the hypercoagulability in these patients.

show abstract

“…The rapid rise in Fl + 2 and the other markers, noticed a few hours after surgery, was probably due t o procoagulant activity released from the injured tissue. With regard to the second peak that occurred on the 9th day, it has been shown that in patients undergoing elective hip surgery there was also a delayed rise in FPA and F1 + 2 occurring on the 7th postoperative day, probably related to wound healing and degradation of haematoma-associated activation of coagulation (Sorensen et al, 1992). These tissue phenomena were probably of major significance in this patient who underwent a bilateral hip arthroplasty in a single procedure.…”

Section: Discussionmentioning

confidence: 70%

Clinical efficacy of a highly purified SD‐treated factor IX concentrate prepared by conventional chromatography

Goudemand

Marey

Caron

et al. 1993

Transfusion Medicine

View full text Add to dashboard Cite

Summary. A highly purified (HP) FIX concentrate was used in 12 patients with haemophilia B in order to prevent bleeding following surgery. The HP FIX concentrate (CRTS, Lille, France) was prepared by ion‐exchange chromatograpy and was SD treated. The patients underwent orthopaedic surgery (3), neurosurgery (3) or multiple dental extraction (6). They were treated for 2–18 days and received 8500 to 102000 FIX units. The mean FIX:C recovery was 0·92 ± 0·20%/U/kg. Satisfactory haemostasis was provided in all patients. None of them experienced thrombotic manifestations. There was no change in FDP or soluble fibrin complexes. Prothrombin fragments one plus two (F1 + 2), thrombin‐antithrombin III complexes (TAT) and cross‐linked fibrin degradation products (D‐dimer) remained in the normal range in one patient treated for 2·5 days for dental surgery. In contrast, elevated levels of F1+2, TAT and D‐dimer were observed in one patient undergoing a bilateral hip arthroplasty treated for 16 consecutive days with the same lot of HP FIX concentrate as the previous patient. There was no seroconversion for HIV, HBV and HCV. These results indicate that the HP FIX concentrate provides satisfactory haemostasis in surgery while avoiding excessive thrombogenic risks. However, some clinical circumstances, such as orthopaedic surgery, are known to be associated with especially high thrombotic risks that must be taken into account in case of FIX replacement.

show abstract

Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin

Cited by 17 publications

References 0 publications

Fibrinogen and Fibrin Derivatives in Traumatized Patients: Relation to Injury Severity and Posttraumatic Pulmonary Dysfunction

Fibrinogen and Fibrin Derivatives in Traumatized Patients: Relation to Injury Severity and Posttraumatic Pulmonary Dysfunction

Pharmacokinetic Study of the Low-Molecular-Weight Heparin Fraxiparin in Patients with Nephrotic Syndrome

Clinical efficacy of a highly purified SD‐treated factor IX concentrate prepared by conventional chromatography

Contact Info

Product

Resources

About